Second hedge fund applies pressure on GSK after taking stakeActivist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing Share XSecond hedge fund applies pressure on GSK after taking stakehttps://pharmaphorum.com/news/second-hedge-fund-applies-pressure-on-gsk-after-taking-stake/
Galapagos’ long-serving CEO Onno van de Stolpe to retireAfter 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided Share XGalapagos’ long-serving CEO Onno van de Stolpe to retirehttps://pharmaphorum.com/news/galapagos-long-serving-ceo-onno-van-de-stolpe-to-retire/
Alex Gorsky will pass leadership of J&J to Joaquin Duato in JanuaryJohnson & Johnson has appointed Joaquin Duato as chief executive officer to replace long-serving Alex Gorsky, who has Share XAlex Gorsky will pass leadership of J&J to Joaquin Duato in Januaryhttps://pharmaphorum.com/news/alex-gorsky-will-pass-leadership-of-jj-to-joaquin-duato-in-january/
With Alzheimer’s market opening up, Lilly forms neuroscience unitEli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the Share XWith Alzheimer’s market opening up, Lilly forms neuroscience unithttps://pharmaphorum.com/news/lilly-forms-neuroscience-unit/
GSK names McNamara as CEO of consumer health spinoutGlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer Share XGSK names McNamara as CEO of consumer health spinouthttps://pharmaphorum.com/news/gsk-names-mcnamara-as-ceo-of-consumer-health-spinout/
Arcus’ CMO Grossman jumps ship to join Gilead’s cancer pushGilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief Share XArcus’ CMO Grossman jumps ship to join Gilead’s cancer pushhttps://pharmaphorum.com/news/arcus-cmo-grossman-jumps-ship-to-join-gileads-cancer-push/
GSK cancer head Hoos exits, takes top role at biotech ScorpionGlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role Share XGSK cancer head Hoos exits, takes top role at biotech Scorpionhttps://pharmaphorum.com/news/gsk-cancer-head-hoos-exits-takes-top-role-at-biotech-scorpion/
GSK backs CEO Walmsley, rejecting Elliott’s call to change boardGlaxoSmithKline’s board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands Share XGSK backs CEO Walmsley, rejecting Elliott’s call to change boardhttps://pharmaphorum.com/news/gsk-backs-ceo-walmsley-rejecting-elliotts-call-to-change-board/
Elliott fires broadside at GSK in wake of investor updateGlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at Share XElliott fires broadside at GSK in wake of investor updatehttps://pharmaphorum.com/news/elliott-fires-broadside-at-gsk-in-wake-of-investor-update/
